Priovant Therapeutics
https://priovanttx.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Priovant Therapeutics
Roivant Won’t Continue With Brepocitinib In Lupus After Phase II Failure
The company wants to focus efforts with the TYK2/JAK1 inhibitor in orphan rheumatology indications like dermatomyositis where current treatment options are inadequate.
Ventyx Won’t Pursue Psoriasis Further Despite Phase II Success
Ventyx’s TYK2 inhibitor met primary and secondary endpoints in a Phase II psoriasis trial, but the biotech determined the data are not competitive in a class led by Bristol’s Sotyktu.
Roivant/Roche: Did Pfizer Miss Out?
Pfizer gave US rights to an asset to Roivant, which turned around and sold it to Roche for $7.1bn 10 months later. Pfizer says it’s content with the 25% stake it will receive. Roivant CEO Matt Gline also talked to Scrip about the sudden turnaround.
Pfizer Returns To Roivant As Development Partner For A Second Time
Roivant will form a new "vant" company to develop and commercialize Pfizer's TL1A inhibitor for ulcerative colitis.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice